{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:40:13Z","timestamp":1788579613972,"version":"build-2803163510"},"reference-count":5,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2023,4,1]]},"abstract":"<jats:p>This cross-sectional study determines the frequency of and rationale for US Food and Drug Administration (FDA) approval of drugs not meeting pivotal trial primary efficacy end points.<\/jats:p>","DOI":"10.1001\/jamainternmed.2022.6444","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T16:01:43Z","timestamp":1676304103000},"page":"376","source":"Crossref","is-referenced-by-count":16,"title":["US Food and Drug Administration Approval of Drugs Not Meeting Pivotal Trial Primary End Points, 2018-2021"],"prefix":"10.1001","volume":"183","author":[{"given":"James L.","family":"Johnston","sequence":"first","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut"},{"name":"National Clinician Scholars Program, Yale School of Medicine, Department of Internal Medicine, New Haven, Connecticut"},{"name":"Yale Collaboration for Regulatory Rigor, Integrity, and Transparency, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshma","family":"Ramachandran","sequence":"additional","affiliation":[{"name":"Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"National Clinician Scholars Program, Yale School of Medicine, Department of Internal Medicine, New Haven, Connecticut"},{"name":"Yale Collaboration for Regulatory Rigor, Integrity, and Transparency, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"ild220053r1","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1056\/NEJMp2110468","article-title":"Revisiting FDA approval of aducanumab.","volume":"385","author":"Alexander","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"ild220053r3","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1001\/jamainternmed.2021.3042","article-title":"Assessment of FDA approval for new high-risk therapeutic devices not meeting pivotal study primary end points, 2016-2020.","volume":"181","author":"Johnston","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"11","key":"ild220053r4","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.7326\/M21-2918","article-title":"U.S. Food and Drug Administration reasoning in approval decisions when efficacy evidence is borderline, 2013-2018.","volume":"174","author":"Janiaud","year":"2021","journal-title":"Ann Intern Med"},{"issue":"12","key":"ild220053r5","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMp1705800","article-title":"The fate of FDA postapproval studies.","volume":"377","author":"Woloshin","year":"2017","journal-title":"N Engl J Med"},{"key":"ild220053r2","unstructured":"Aduhelm (aducanumab-avwa) BLA761178 Clinical Review. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Published June 7, 2021. Accessed January 8, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/761178Orig1s000MedR_Redacted.pdf"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2801023\/jamainternal_johnston_2023_ld_220053_1680275744.71968.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T15:20:51Z","timestamp":1680535251000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2801023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":5,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2022.6444","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,1]]}}}